Last reviewed · How we verify
BCG Sii
BCG Sii is a live attenuated Mycobacterium bovis BCG vaccine strain designed to stimulate innate and adaptive immune responses.
BCG Sii is a live attenuated Mycobacterium bovis BCG vaccine strain designed to stimulate innate and adaptive immune responses. Used for COVID-19 prevention or therapeutic immunization (investigational).
At a glance
| Generic name | BCG Sii |
|---|---|
| Also known as | Bacille Calmette-Guérin Serum Institute of India |
| Sponsor | University of Oxford |
| Drug class | Live attenuated vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
BCG (Bacillus Calmette-Guérin) is a live attenuated mycobacterial vaccine that activates both innate immunity through pattern recognition receptors and adaptive immunity through T-cell and B-cell responses. The Sii strain variant from the Serum Institute of India is being investigated for enhanced immunogenicity. In phase 3 development, it is being studied for potential therapeutic applications beyond traditional tuberculosis prevention.
Approved indications
- COVID-19 prevention or therapeutic immunization (investigational)
Common side effects
- Local injection site reactions (erythema, induration)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) (PHASE2)
- Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (PHASE3)
- Heterologous Effects of BCG in Healthy UK Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |